Translational Lung Cancer Research

Papers
(The H4-Index of Translational Lung Cancer Research is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Prolonged disease control with local treatments in oligo-acquired resistance to immune-checkpoint inhibitors52
Density and maturity ratio of tertiary lymphoid structures in stage II–III non-small cell lung cancer predict postoperative recurrence risk50
Proteomic analysis of plasma exosomes in patients with non-small cell lung cancer42
Evaluation of gut leakage and bacterial translocation as efficacy biomarkers of immunotherapy in advanced non-small cell lung cancer (NSCLC)40
Whole genome characterization of patient-derived lung cancer organoids38
Comparison of efficacy and surgery-related safety of perioperative tislelizumab and pembrolizumab with neoadjuvant chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study35
Tackling the challenge of brain involvement in driver-negative non-small cell lung cancer33
DNA hypomethylation-activated PRAME drives early-stage lung adenocarcinoma recurrence via ZNF740 and PI3K/AKT/mTOR signaling30
Contrast-enhanced CT and PET-CT characteristics of primary tracheal lymphoepithelioma-like carcinoma: case series29
Landscape and clinical impact of metabolic alterations in non-squamous non-small cell lung cancer28
Long-term survival after combination therapy with atezolizumab in a patient with small-cell lung cancer: a case report28
The epidemic of malignant mesothelioma in China: a prediction of incidence during 2016–203027
Targeting ferroptosis to overcome drug resistance in lung cancer27
PFKP confers chemoresistance by upregulating ABCC2 transporter in non-small cell lung cancer27
Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review26
Prognostic factors of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor (TKI): a nationwide registry study in China26
Metachronous development of L858R and T790M EGFR mutations following ALK inhibitor therapy in stage IV lung adenocarcinoma: a case report26
Molecular and clinical disparity of EGFR-mutant non-small cell lung cancer (NSCLC) based on histopathological stage and EGFR molecular subtypes26
Efficacy and safety of lorlatinib in first-line and subsequent-line treatments for patients with ALK-positive non-small cell lung cancer: a single-center real-world study in China25
Real-world data on severe lung cancer: a multicenter retrospective study25
Microbiota modulate lung squamous cell carcinoma lymph node metastasis through microbiota-geneset correlation network25
Optimizing long-term treatment with ALK inhibitors: balancing efficacy and safety24
Molecular mechanism and clinical outcome of non-small cell lung cancer patients with high BRAF expression24
Predictive value of perioperative carcinoembryonic antigen changes for recurrence in non-small cell lung cancer24
0.051012992858887